Type
|
Public |
---|---|
Traded as | NASDAQ: PPHM,NASDAQ: PPHMP |
Industry | Pharmaceuticals |
Founded | 1981 |
Headquarters | Tustin, California, United States |
Key people
|
Steven W. King (President and CEO) |
Revenue | US$ 26.781 million (2015) |
Operating income
|
US$ -50.499 million (2015) |
Net income
|
US$ -50.358 million (2015) |
Total assets | US$ 97.464 million (2015) |
Total equity | US$ 97.646 million (2015) |
Number of employees
|
215 (April 30, 2015) |
Website | www.peregrineinc.com |
Peregrine Pharmaceuticals, Inc. is a publicly-traded American biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials as potential cancer treatments and diagnostic agents. As of 2016 their lead product candidate was bavituximab. It also has a revenue-generating subsidiary, Avid Bioservices, which is a contract manufacturing organization that provides services to Peregrine and to other companies.
Peregrine was founded in 1981.
In 2002 Peregrine established a wholly owned subsidiary, Avid Bioservices, a contract manufacturing organization that provides cGMP development and biomanufacturing services for both Peregrine and outside customers. In 2015 Avid had revenues of about $27 million, about 80% of which came under contract from Halozyme Therapeutics.
Bavituximab (PGN401) is a human-mouse chimeric monoclonal antibody against phosphatidylserine, which is a component of cell membranes that is exposed when a cell is transformed into solid tumor cancer cell or dies, and when cells are infected with hepatitis C. The process of cell death is highly controlled and so there usually no immune response to phosphatidylserine but when bavituximab binds to it, the conjugate appears to stimulate an immune response in humans.
I-PGN650 is a phosphatidylserine-targeting F(ab')2 fully human monoclonal antibody fragment joined to the PET imaging radio-isotope iodine-124 being developed to obtain medical images of cancer.
Cotara (I-chTNT-1/B) is a chimeric monoclonal antibody against DNA-histone H1 complex called TNT-1, conjugated to the radioisotope iodine-131. As of 2016 Peregrine was developing it for Glioblastoma multiforme; it has been granted orphan status in Europe and the US.
2016-06-04 | Reiterated Rating | FBR & Co. | Buy | $1.00 |
2016-06-04 | Reiterated Rating | FBR & Co | Buy | $1.00 |
2016-05-20 | Reiterated Rating | FBR & Co. | Outperform | $1.00 |
2016-04-23 | Reiterated Rating | FBR & Co. | Buy | |
2016-03-04 | Lower Price Target | FBR & Co. | Outperform | $3.50 to $1.00 |
2016-02-28 | Reiterated Rating | FBR & Co. | Outperform | $3.50 to $1.00 |
2016-02-26 | Downgrade | Roth Capital | Buy to Neutral | $3.00 to $0.50 |
2016-01-22 | Reiterated Rating | Roth Capital | Buy | $3.00 |
2016-01-14 | Reiterated Rating | FBR & Co. | Outperform | $3.50 |
2016-01-12 | Initiated Coverage | FBR & Co. | Buy | |
2015-12-14 | Reiterated Rating | Noble Financial | Buy | $5.00 |
2015-10-30 | Reiterated Rating | FBR & Co. | Outperform | |
2015-08-25 | Reiterated Rating | Roth Capital | Buy | $5.00 |
2015-07-16 | Reiterated Rating | Roth Capital | Buy | |
2015-07-16 | Initiated Coverage | Noble Financial | Buy | $5.00 |
2015-06-10 | Set Price Target | Roth Capital | Buy | $5.00 |
2015-06-01 | Reiterated Rating | MLV & Co. | Buy | $3.50 |
2015-04-20 | Set Price Target | Roth Capital | Buy | $5.00 |
2015-03-13 | Set Price Target | MLV & Co. | Buy | $3.50 |
2014-07-15 | Reiterated Rating | Roth Capital | Buy | |
2014-03-11 | Reiterated | MLV & Co | Buy | $2.50 to $3.50 |
2014-03-11 | Reiterated | |||
2014-03-11 | Boost Price Target | MLV & Co. | Buy | $2.50 to $3.50 |
2014-01-17 | Lower Price Target | JPMorgan Chase & Co. | $12.00 to $9.50 | |
2012-09-27 | Resumed | MLV & Co | Buy | $4.50 to $2 |
2011-08-30 | Initiated | JMP Securities | Mkt Outperform | $5 |
2016-06-04 | Reiterated Rating | FBR & Co. | Buy | $1.00 |
2016-06-04 | Reiterated Rating | FBR & Co | Buy | $1.00 |
2016-05-20 | Reiterated Rating | FBR & Co. | Outperform | $1.00 |
2016-04-23 | Reiterated Rating | FBR & Co. | Buy | |
2016-03-04 | Lower Price Target | FBR & Co. | Outperform | $3.50 to $1.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In PPHM 8 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Institutional Trust Company, N.A. | 4.24M |
BLACKROCK ADVISORS LLC | 0.45M |
FIDGEON TIMOTHY F | 0.12M |
RUSSELL FRANK CO/ | 76400 |
BlackRock Fund Advisors | 53110 |
Airain ltd | 42362 |
KCG Holdings, Inc. | 20834 |
MetLife Securities, Inc | 6000 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
LYTLE PAUL J Chief Financial Officer | 0.10% (184038) | PPHM / |
SWARTZ ERIC S | 0.07% (126000) | PPHM / |
Fussey Shelley PM VP, Intellectual Property | 0.06% (110475) | PPHM / |
Bamforth Mark R | 0.06% (100000) | PPHM / |
McComb Joel | 0.03% (50000) | PPHM / |
CARLEONE JOSEPH | 0.02% (44445) | APFC / PPHM / SXT / |
KING STEVEN W President & CEO | 0.02% (34646) | PPHM / |
Shan Joseph VP Clinical/Regulatory Affairs | 0.01% (16187) | PPHM / |
Masten Jeffrey L. V.P. Quality | 0.01% (12498) | PPHM / |